Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trial
Iberdomide showed beneficial effects when added to background lupus medications in patients with subacute and chronic CLE.
Authors
- Ronald van Vollenhoven (ORCID: https://orcid.org/0000-0001-6438-8663)
- Thomas E. Dorner (ORCID: https://orcid.org/0000-0002-5218-1160)
- Michael Weiswasser
- MARK B. STERN
- Victoria P. Werth (ORCID: https://orcid.org/0000-0003-3030-5369)
- Nikolay Delev
- Peter E. Lipsky (ORCID: https://orcid.org/0000-0002-9287-1676)
- Joan T. Merrill (ORCID: https://orcid.org/0000-0002-4514-2382)
- Shimon Korish
- Richard Furie (ORCID: https://orcid.org/0000-0001-6712-1585)
- Stan Z. Li (ORCID: https://orcid.org/0000-0002-2961-8096)
- Peter Schäfer (ORCID: https://orcid.org/0000-0002-3880-0850)
Institutions
- Northwell Health (US)
- Oklahoma Medical Research Foundation (US)
- Bristol-Myers Squibb (United States) (US)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- Journal of the American Academy of Dermatology
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1016/j.jaad.2024.09.074
- Citations
- 6
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 2.82
Funders
- Bristol-Myers Squibb